EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design

Cameron Andress iD, Kalli Kappel, Marcus Elbert Villena, Miroslava Cuperlovic-Culf iD, Hongbin Yan, Yifeng Li

PLOS Computational Biology · 2023

DOI: 10.1371/journal.pcbi.1010774 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, 2023. Verfasst von Cameron Andress und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Computer Science, Brock University, St. Catharines, Canada. Hauptthemen laut MEDLINE: Aptamers, Nucleotide, COVID-19. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Council Canada, Natural Sciences and Engineering Research Council of Canada, OGS - Ontario Graduate Scholarship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Typical drug discovery and development processes are costly, time consuming and often biased by expert opinion. Aptamers are short, single-stranded oligonucleotides (RNA/DNA) that bind to target proteins and other types of biomolecules. Compared with small-molecule drugs, aptamers can bind to their targets with high affinity (binding strength) and specificity (uniquely interacting with the target only). The conventional development process for aptamers utilizes a manual process known as Systematic Evolution of Ligands by Exponential Enrichment (SELEX), which is costly, slow, dependent on library choice and often produces aptamers that are not optimized. To address these challenges, in this research, we create an intelligent approach, named DAPTEV, for generating and evolving aptamer sequences to support aptamer-based drug discovery and development. Using the COVID-19 spike protein as a target, our computational results suggest that DAPTEV is able to produce structurally complex aptamers with strong binding affinities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aptamers, NucleotideCOVID-19HumansSELEX Aptamer TechniqueDrug DesignRNALigands

Substanzen

Aptamers, NucleotideRNALigands

Autor:innen und Institutionen

  • Department of Computer Science, Brock University, St. Catharines, Canada.
  • Broad Institute of MIT and Harvard, Cambridge, Massachusetts, United States of America.
  • Department of Biological Sciences, Brock University, St. Catharines, Canada.
  • Digital Technologies Research Centre, National Research Council Canada, Ottawa, Canada.
  • Department of Chemistry, Brock University, St. Catharines, Canada.

ORCID-Profile: Cameron Andress, Miroslava Cuperlovic-Culf

Förderung

  • National Research Council Canada
  • Natural Sciences and Engineering Research Council of Canada
  • OGS - Ontario Graduate Scholarship
  • Schmidt Science Fellows, in partnership with the Rhodes Trust, and the HHMI Hanna H. Gray Fellows Program

Zitieren

APA

Andress, C., Kappel, K., Villena, M. E., Cuperlovic-Culf, M., Yan, H., & Li, Y. (2023). DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design. PLOS Computational Biology. https://doi.org/10.1371/journal.pcbi.1010774

Vancouver

Andress C, Kappel K, Villena ME, Cuperlovic-Culf M, Yan H, Li Y. DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design. PLOS Computational Biology. 2023. doi:10.1371/journal.pcbi.1010774

BibTeX
@article{Andress2023,
  author = {Andress, Cameron and Kappel, Kalli and Villena, Marcus Elbert and Cuperlovic-Culf, Miroslava and Yan, Hongbin and Li, Yifeng},
  title = {DAPTEV: Deep aptamer evolutionary modelling for COVID-19 drug design},
  journal = {PLOS Computational Biology},
  year = {2023},
  doi = {10.1371/journal.pcbi.1010774}
}
Kostenlos starten →